Prosecution Insights
Last updated: April 19, 2026
Application No. 18/108,171

HYDROGEL MICROPARTICLES FOR APPLICATIONS IN CELL AND PARTICLE SEPARATION

Non-Final OA §103
Filed
Feb 10, 2023
Examiner
GIERE, REBECCA M
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Charles Stark Draper Laboratory Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
3y 2m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
364 granted / 495 resolved
+13.5% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
42 currently pending
Career history
537
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
42.0%
+2.0% vs TC avg
§102
21.3%
-18.7% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 495 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-20 are pending. Claims 1-12 and 19-20 have been withdrawn as drawn to non-elected inventions. Claims 13-18 have been examined. Election/Restriction Applicant’s election without traverse of Group II, claims 13-18, in the reply filed on 11/17/2025 is acknowledged. Priority This application, Serial No. 18/108,171 (PGPub: US2023/0258636) was filed 02/10/2023. This application claims benefit of provisional application 63/309,225 filed 02/11/2022. Information Disclosure Statements The Information Disclosure Statement filed 02/17/2023 has been considered by the Examiner. Claim Objections Claim 18 is objected to because of the following informalities: Claim 18 should be corrected to recite “…wherein the one or more synthetic particles are modified according…” Appropriate correction is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 13-18 are rejected under 35 U.S.C. 103 as being unpatentable over Han et al. (US 2020/0391169, Pub Date: 12/17/2020). Regarding claim 13, Han teaches throughout the publication a system (see Figure 2A), comprising: one or more input streams that receive input material to be provided to a droplet generator, the input material selected based on a set of synthetic particle characteristics comprising a synthetic particle density and one or more other physical properties (Figure 2A, component at 220; paragraphs 0105-0110, characteristics to consider include particle density, particle diameter, hydrogel volume, polymer/hydrogel material); and an output stream that receives one or more synthetic particles created by the droplet generator, the one or more synthetic particles having the set of synthetic particle characteristics (Figure 2A, component at 210; paragraphs 0105-0110, wherein a surface characteristic of the one or more synthetic particles are modified to cause the one or more synthetic particles to bind to one or more target particles in a solution (paragraph 0113, following hydrogel particle synthesis, beads are conjugated to a specific antibody that targets a desired protein biomarker). While Han does not explicitly recite that the synthetic particles are modified in a reservoir that stores the one or more synthetic particles, the reference teaches an in depth functionalization process that includes washing, mixing, suspending and centrifuging the beads to enable covalent coupling (see paragraph 0155). It would have been obvious to one having ordinary skill in the art at the time the invention was filed that the functionalization process of Han was conducted within a reservoir that stores the particles as the steps taught by Han are well-known in the art to be conducted within a tube or vial, which reads on the broadly claimed reservoir. Regarding claim 14, Han teaches the system wherein the one or more other physical properties include a size of the one or more synthetic particles (paragraph 0108). Regarding claim 15, Han teaches the system wherein the input material comprises a polymer selected to modulate a particle density of the one or more synthetic particles (paragraphs 0011 and 0029, polymer to modulate particle density). Regarding claim 16, Han teaches the system wherein the one or more synthetic particles comprise a hydrogel (paragraphs 0011-0013). Regarding claim 17, Han teaches the system wherein the input material comprises an additive including a metal oxide (paragraph 0124, iron oxide nanoparticles added to the aqueous phase with the monomers and crosslinkers). Regarding claim 18, Han teaches the system wherein the one or more synthetic particles modified according to a surface treatment including applying antibodies to the one or more synthetic particles (paragraphs 0041 and 0113 and for example, paragraph 0155, antibody functionalization). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Chung et al., (ACS Appl. Bio Mater. 2021, 4, pages 6186-6194) teaches a droplet based microfluidic synthesis method for fabrication of hydrogel microparticles (abstract). Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA M GIERE whose telephone number is (571)272-5084. The examiner can normally be reached M-F 8:30-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy L Nguyen can be reached at 571-272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA M GIERE/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Feb 10, 2023
Application Filed
Dec 12, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12571804
AUTOMATIC TEST CARD FOR MULTI-BLOOD GROUP SYSTEM AND TEST METHOD
2y 5m to grant Granted Mar 10, 2026
Patent 12571035
METHOD OF TARGET MOLECULE CHARACTERISATION USING A MOLECULAR PORE
2y 5m to grant Granted Mar 10, 2026
Patent 12560599
SAMPLE CLARIFICATION AND REDUCTION OF BACKGROUND FLUORESCENCE FOR FLUORESCENT DETECTION OF ANALYTES
2y 5m to grant Granted Feb 24, 2026
Patent 12544755
WHOLE-PROCESS BIOLOGICAL DETECTION DEVICE
2y 5m to grant Granted Feb 10, 2026
Patent 12529656
BIOMOLECULAR ANALYSIS METHOD AND BIOMOLECULAR ANALYZER
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+32.8%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 495 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month